Leerink Boosts PT on Nuance Communications (NUAN) to $21 Following Q4 Results, Strong Outlook

Leerink is raising its price target on Outperform-rated Nuance Communications (Nasdaq: NUAN) from $19 to $21 following Q4 results and solid FY16 guidance issued Monday night.

Analyst Steven Wardell noted positives and negatives from the quarter:

Positives -

• The Transformation Program is working, 4Q beat of $0.06 driven by strong cost cutting execution.
• Healthcare is driving the company's 2016G bookings growth of ~4% with important contributions from Clintegrity, Dragon Medical, and Diagnostics. Management expects continued hospital focus on clinical documentation in 2016 to support Clintegrity growth, strengthened by ICD-10 upgrade.
• Revenue model transition in mid-to-late stages as Revenue mix approx. 68% from recurring (up from 63% y/y).
• Strong '15 Automotive bookings looks to be a key driver of revenue growth in '16.

Negatives -

• Operating results still face drag of revenue model transition and erosion of older lines of business.
• Topline growth remains elusive with 1.3% growth in '16G.

For an analyst ratings summary and ratings history on Nuance Communications click here. For more ratings news on Nuance Communications click here.

You May Also Be Interested In

• Take-Two Interactive (TTWO) PT Raised to $368 at BofA Securities
• Cytokinetics (CYTK) PT Raised to $118 at Mizuho
• ChargePoint Holdings Inc. (CHPT) PT Raised to $8 at UBS as Cost Discipline Improves